194 related articles for article (PubMed ID: 21369702)
1. Clinical significance of circulating galectins as colorectal cancer markers.
Watanabe M; Takemasa I; Kaneko N; Yokoyama Y; Matsuo E; Iwasa S; Mori M; Matsuura N; Monden M; Nishimura O
Oncol Rep; 2011 May; 25(5):1217-26. PubMed ID: 21369702
[TBL] [Abstract][Full Text] [Related]
2. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
3. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
4. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
[TBL] [Abstract][Full Text] [Related]
5. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of tumor markers and evaluation of their predictive value in patients with colorectal cancer.
Liu ZP; Li LM; Liu XL; Zhang DX
Onkologie; 2012; 35(3):108-13. PubMed ID: 22414974
[TBL] [Abstract][Full Text] [Related]
7. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
[TBL] [Abstract][Full Text] [Related]
9. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
10. [Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients].
Grotowski M; Maruszyński M; Piechota W
Pol Merkur Lekarski; 2001 Dec; 11(66):476-9. PubMed ID: 11899841
[TBL] [Abstract][Full Text] [Related]
11. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
12. Alu-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer.
Qi J; Qian C; Shi W; Wu X; Jing R; Zhang L; Wang Z; Ju S
Clin Biochem; 2013 Jan; 46(1-2):64-9. PubMed ID: 22975639
[TBL] [Abstract][Full Text] [Related]
13. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
14. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring.
Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Liu BY; Zhu ZG
J Gastroenterol Hepatol; 2005 Dec; 20(12):1913-9. PubMed ID: 16336453
[TBL] [Abstract][Full Text] [Related]
15. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M
Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603
[TBL] [Abstract][Full Text] [Related]
16. Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker panel.
Yeh CS; Wang JY; Wu CH; Chong IW; Chung FY; Wang YH; Yu YP; Lin SR
Int J Oncol; 2006 Feb; 28(2):411-20. PubMed ID: 16391796
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers in patients with relapse of colorectal carcinoma.
Lipská L; Visokai V; Levý M; Svobodová S; Kormunda S; Fínek J
Anticancer Res; 2007; 27(4A):1901-5. PubMed ID: 17649792
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin serum biomarkers in patients with colorectal cancer.
Holdenrieder S; Stieber P; Liska V; Treska V; Topolcan O; Dreslerova J; Matejka VM; Finek J; Holubec L
Anticancer Res; 2012 May; 32(5):1971-6. PubMed ID: 22593474
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients.
Nakagoe T; Sawai T; Tsuji T; Jibiki MA; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K
Hepatogastroenterology; 2003; 50(51):696-9. PubMed ID: 12828063
[TBL] [Abstract][Full Text] [Related]
20. CEA in activated macrophages. New diagnostic possibilities for tumor markers in early colorectal cancer.
Japink D; Leers MP; Sosef MN; Nap M
Anticancer Res; 2009 Aug; 29(8):3245-51. PubMed ID: 19661342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]